Liraglutide (CAS 204656-20-2) is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist API, renowned for its powerful and sustainable weight-loss effects. Its bioactive molecular structure mimics the natural GLP-1 hormone, effectively suppressing appetite, slowing gastric emptying, and regulating glucose metabolism—delivering dual benefits of weight management and metabolic health.
As a high-purity pharmaceutical raw material, it exhibits excellent potency and stability, adhering to global pharmacopoeial standards. Beyond core weight-loss benefits, it supports healthy blood sugar control and reduces cravings for high-calorie foods, making it ideal for formulating medications targeting obesity and related metabolic disorders.
For pharmaceutical manufacturers and healthcare product developers, this API offers a science-backed solution to meet the growing demand for safe, effective weight-management ingredients. Its mechanism of action aligns with physiological processes, ensuring tolerability and long-term compliance for users seeking sustainable weight loss.
